SuperGen have announced that the U.S. FDA has granted orphan drug designation for the company’s lead drug candidate, MP-470 in the the treatment of glioblastoma multiforme. MP-470 inhibits c-MET, c-RET, c-KIT, PDGFR and FLT3
Filed under: Uncategorized | Tagged: c-kit, c-met, c-RET, ckit, cmet, cret, FDA, FLT3, MP-470, mp470, PDGFR, regulatory, Supergen | Comments Off
Nycomed have completed the sale of a preclinical kinase program comprising two potential drug candidates and an extensive back-up program to Bayer Schering. This deal follows Nycomed’s strategic decision not to further invest in oncology R&D activities.
Filed under: kinase | Tagged: bayer, bayer-schering, kinase, licensing, nycomed, Preclinical, Research | Comments Off
